CA
NZ
UK
AU
IND
US
…
Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. The company's product pipeline includes RYTELO, a telomerase inhibitor for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia; IMerge which is in Phase 3 clinical trial for the treatment of lower-risk myelodysplastic syndromes; IMpactMF that is in Phase 3 for the treatment of relapsed/refractory myelofibrosis; Impress which is in Phase 2 clinical trial to treat higher risk myelodysplastic syndromes and acute myeloid leukemia (AML); IMproveMF which is in Phase 1 clinical trial for the treatment of frontline myelofibrosis; and IMAGINE which is in phase 1/2 clinical trial for the treatment of relapsed/refractory AML. Geron Corporation was incorporated in 1990 and is headquartered in Foster City, California.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Geron Corporation is a clinical-stage biopharmaceutical company focused on developing imetelstat, a telomerase inhibitor being evaluated for myelofibrosis and lower-risk myelodysplastic syndromes. Long-term growth could be driven by clinical trial success, regulatory approvals and potential partnerships, and investors may find the company attractive because the mechanism targets unmet needs in marrow-failure disorders.
Main risks are binary clinical and regulatory outcomes, dependence on a single candidate with limited revenue, and likely need for additional financing.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -85.78M | -174.57M | -184.13M | -141.90M | -116.11M |
| Net income | -85.78M | -174.57M | -184.13M | -141.03M | -120.95M |
| Selling general administrative | 159.26M | 145.73M | 69.14M | 43.63M | 29.66M |
| Selling and marketing expenses | - | - | 1.03M | - | - |
| Gross profit | 179.14M | 75.74M | 0.24M | 0.60M | 1.39M |
| Reconciled depreciation | 1.20M | 1.22M | 1.03M | 0.87M | 0.78M |
| Ebit | -53.12M | -156.07M | -175.81M | -138.55M | -114.00M |
| Ebitda | -51.92M | -154.85M | -174.78M | -135.02M | -111.59M |
| Depreciation and amortization | 1.20M | 1.22M | 1.03M | 3.53M | 2.41M |
| Non operating income net other | - | - | - | 3.53M | 1.63M |
| Operating income | -53.84M | -173.73M | -193.94M | -138.55M | -114.00M |
| Other operating expenses | 237.72M | 250.73M | 194.18M | 139.15M | 115.39M |
| Interest expense | 32.66M | 18.50M | 8.31M | 6.88M | 3.74M |
| Interest income | 18.12M | 19.61M | 18.15M | 2.53M | 0.53M |
| Net interest income | -14.54M | 1.10M | 9.84M | -4.35M | -3.21M |
| Income tax expense | - | - | 0.00M | -0.87M | 4.84M |
| Total revenue | 183.88M | 76.99M | 0.24M | 0.60M | 1.39M |
| Total operating expenses | 232.97M | 249.47M | 194.18M | 139.15M | 115.39M |
| Cost of revenue | 4.75M | 1.26M | 123.74M | - | - |
| Total other income expense net | -31.95M | -0.84M | 9.82M | -3.35M | -2.11M |
| Net income from continuing ops | -83.50M | -174.57M | -184.13M | -141.90M | -116.11M |
| Net income applicable to common shares | - | - | - | -141.90M | -116.11M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 570.54M | 593.78M | 394.08M | 190.57M | 226.03M |
| Other current assets | 121.25M | 6.91M | 4.88M | 7.14M | 3.12M |
| Total liab | 344.67M | 313.46M | 146.13M | 110.58M | 99.62M |
| Total stockholder equity | 225.87M | 280.32M | 247.95M | 80.00M | 126.42M |
| Other current liab | 80.84M | 78.73M | 54.07M | 44.63M | 37.93M |
| Common stock | 0.64M | 0.61M | 0.55M | 0.39M | 0.32M |
| Capital stock | 0.64M | 0.61M | 0.55M | 0.39M | 0.32M |
| Retained earnings | -1855.84M | -1772.34M | -1597.77M | -1413.64M | -1271.74M |
| Other assets | - | 0.00M | - | 5.39M | 4.80M |
| Cash | 79.44M | 79.02M | 71.14M | 57.21M | 34.87M |
| Total current liabilities | 111.54M | 88.30M | 108.07M | 76.69M | 45.52M |
| Net debt | 172.13M | 42.70M | 14.76M | -1.46M | 20.13M |
| Short term debt | 19.45M | 0.97M | 47.84M | 21.87M | 0.90M |
| Short long term debt | - | - | 46.89M | 20.95M | - |
| Short long term debt total | 251.57M | 121.72M | 85.90M | 55.75M | 55.00M |
| Other stockholder equity | 2080.80M | 2051.79M | 1844.99M | 1493.47M | 1398.01M |
| Property plant equipment | - | - | - | 0.79M | 0.65M |
| Total current assets | 520.27M | 490.99M | 341.35M | 180.25M | 187.21M |
| Long term investments | 41.29M | 94.52M | 43.30M | 0.00M | 28.65M |
| Net tangible assets | - | - | - | 80.00M | 126.42M |
| Short term investments | 280.36M | 327.55M | 263.68M | 115.90M | 148.85M |
| Net receivables | 39.23M | 38.80M | 1.66M | 3.14M | 1.76M |
| Long term debt | 119.55M | 118.48M | 35.05M | 30.21M | 49.83M |
| Inventory | 116.64M | 38.71M | - | -3.14M | -1.40M |
| Accounts payable | 11.26M | 8.60M | 6.16M | 10.19M | 6.69M |
| Accumulated other comprehensive income | 0.27M | 0.26M | 0.18M | -0.22M | -0.17M |
| Common stock total equity | - | - | - | 0.39M | 0.32M |
| Retained earnings total equity | - | - | - | -1413.64M | -1271.74M |
| Non currrent assets other | 8.10M | 4.08M | 4.70M | 9.54M | 4.80M |
| Non current assets total | 50.27M | 102.79M | 52.73M | 10.33M | 38.83M |
| Capital lease obligations | 2.44M | 3.24M | 3.96M | 4.60M | 5.17M |
| Long term debt total | - | - | - | 30.21M | 49.83M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | 107.30M | -106.00M | -180.32M | 62.50M | 70.56M |
| Change to liabilities | - | - | - | 10.20M | 14.56M |
| Total cashflows from investing activities | 107.25M | -106.00M | -180.32M | 62.07M | 71.95M |
| Net borrowings | 0.00M | 34.57M | 29.70M | - | 24.89M |
| Total cash from financing activities | 2.27M | 334.37M | 362.02M | 87.26M | 48.56M |
| Change to operating activities | - | - | - | 1.52M | 10.75M |
| Net income | -85.78M | -174.57M | -184.13M | -141.90M | -116.11M |
| Change in cash | -1.44M | 9.74M | 13.93M | 21.97M | 24.95M |
| Begin period cash flow | 80.88M | 71.14M | 57.21M | 35.23M | 10.29M |
| End period cash flow | 79.44M | 80.88M | 71.14M | 57.21M | 35.23M |
| Total cash from operating activities | -111.04M | -218.62M | -167.74M | -127.38M | -95.56M |
| Issuance of capital stock | 0.00M | 140.73M | 213.34M | 69.92M | 20.39M |
| Depreciation | 1.20M | 1.22M | 1.03M | 0.87M | 0.78M |
| Other cashflows from investing activities | - | - | -179.49M | - | 1.59M |
| Change to inventory | -77.92M | -37.97M | 0.00M | - | - |
| Change to account receivables | -0.38M | -36.89M | 1.49M | - | - |
| Sale purchase of stock | - | - | - | 17.35M | 23.66M |
| Other cashflows from financing activities | 2.27M | 159.08M | 118.98M | 17.35M | 28.17M |
| Change to netincome | - | - | - | 8.27M | 6.94M |
| Capital expenditures | 0.05M | 0.68M | 0.83M | 0.43M | 0.21M |
| Cash flows other operating | - | - | - | -4.60M | -3.47M |
| Cash and cash equivalents changes | - | - | - | 21.95M | 24.95M |
| Change in working capital | -68.54M | -68.41M | 6.06M | 5.03M | 10.52M |
| Stock based compensation | 0.09M | 31.32M | 19.35M | 8.00M | 8.08M |
| Other non cash items | 41.99M | -8.18M | -10.06M | 0.63M | 0.98M |
| Free cash flow | -111.09M | -219.30M | -168.57M | -127.81M | -95.76M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| GERN Geron Corporation |
-0.18 15.78% |
0.97 | - | 68.03 | 4.11 | 4.01 | 3.41 | -9.06 |
| NVO Novo Nordisk A/S |
-0.38 0.98% |
38.29 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
8.66 1.66% |
529.69 | 30.22 | 24.27 | 10.36 | 6.50 | 9.99 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
-2.83 0.35% |
813.27 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
| ARGNF argenx SE |
- -% |
790.15 | 45.77 | 31.25 | 13.84 | 7.12 | 11.38 | 36.06 |
Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. The company's product pipeline includes RYTELO, a telomerase inhibitor for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia; IMerge which is in Phase 3 clinical trial for the treatment of lower-risk myelodysplastic syndromes; IMpactMF that is in Phase 3 for the treatment of relapsed/refractory myelofibrosis; Impress which is in Phase 2 clinical trial to treat higher risk myelodysplastic syndromes and acute myeloid leukemia (AML); IMproveMF which is in Phase 1 clinical trial for the treatment of frontline myelofibrosis; and IMAGINE which is in phase 1/2 clinical trial for the treatment of relapsed/refractory AML. Geron Corporation was incorporated in 1990 and is headquartered in Foster City, California.
919 East Hillsdale Boulevard, Foster City, CA, United States, 94404
650 473 7700
258
| Name | Title | Year Born |
|---|---|---|
| Dr. John A. Scarlett M.D. | Chairman, Pres & CEO | 1951 |
| Ms. Olivia Kyusuk Bloom | Exec. VP of Fin., CFO & Treasurer | 1969 |
| Dr. Andrew J. Grethlein | Exec. VP & COO | 1964 |
| Ms. Melissa A. Kelly Behrs | Exec. VP of Bus. Operations & Chief Alliance Officer | 1964 |
| Mr. Anil Kapur | Exec. VP of Corp. Strategy & Chief Commercial Officer | 1970 |
| Ms. Aron Feingold | VP of Investor Relations & Corp. Communications | NA |
| Mr. Stephen N. Rosenfield J.D. | Exec. VP, Chief Legal Officer & Corp. Sec. | 1950 |
| Ms. Shannon Odam | VP of HR | NA |
| Mr. Edward E. Koval | Exec. VP & Chief Bus. Officer | 1962 |
| Dr. Faye Feller M.D. | Exec. VP & Chief Medical Officer | 1982 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
+0.02%
Communication Services
-0.63%
Consumer Cyclical
-0.11%
Consumer Defensive
-0.45%
Energy
+0.39%
Financial Services
-0.10%
Financials
-0.81%
Healthcare
+1.03%
Industrials
+0.32%
Real Estate
-0.31%
Technology
+0.59%
Utilities
-0.18%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...